In what experts are calling the most significant breakthrough in HIV prevention since the epidemic began, the Food and Drug Administration (FDA) on Wednesday approved Yeztugo, a long-acting injectable drug that provides protection against HIV for six months with a single shot.

The drug — chemically known as lenacapavir — is poised to transform global public health. For the first time, at-risk individuals can shield themselves from HIV infection without the burden of daily pills. Yet, despite the medical milestone, looming barriers from past political decisions may delay or even derail the drug’s true potential.

“It really could be a game changer,” said Dr. John Brooks, former chief medical officer at the CDC’s division of HIV prevention. “Especially in regions where HIV is still devastating communities — from parts of Africa to the American South.”

The Science of Prevention

Yeztugo works by blocking a protein essential to HIV replication. Administered via subcutaneous injection just twice a year, the drug has shown efficacy rates exceeding 95% in clinical trials. Compared to existing PrEP (pre-exposure prophylaxis) regimens — which require daily pills — this bi-annual injection drastically reduces issues of adherence, one of the major reasons PrEP has failed to fully curb HIV spread.

“People live busy, chaotic lives,” said Dr. Fiona Redding, an infectious disease expert at Emory University. “The beauty of Yeztugo is that it takes one of the hardest parts of HIV prevention — consistency — out of the equation.”

A Pandemic Still Unfolding

More than 38 million people live with HIV globally. While antiretroviral therapies have extended lifespans and improved quality of life, prevention remains a top public health priority. In the U.S. alone, over 30,000 new infections are recorded annually — many in under-resourced communities with limited access to consistent care.

“This could be the thing that ends it,” said Anthony Thomas, an HIV advocate in Atlanta. “But only if the government doesn’t screw it up.”

The Trump-Era Trap

Despite Yeztugo’s promise, it enters a regulatory and political climate shaped by deep scars from the Trump administration. Under President Trump, federal health agencies saw funding cuts to HIV outreach, PrEP education, and LGBTQ+ health programs — particularly those targeting Black and Latino gay men, who bear the brunt of new infections in the U.S.

Worse still, some of the insurance mandates for HIV prevention coverage — set in motion under the Affordable Care Act — were weakened by conservative legal challenges in federal courts. Advocates now fear Yeztugo may fall into a coverage gap, with vulnerable people priced out of protection.

“The science is here,” said Dr. Redding. “What’s missing is political will.”

Gilead’s Price Tag Problem

Then there’s the issue of cost. Gilead Sciences, the drug’s manufacturer, has not yet released an official price — but speculation runs high. Gilead’s other HIV prevention drug, Descovy, can cost upwards of $2,000 a month without insurance.

“We’re staring at a miracle, but it’s a miracle that could be locked behind a paywall,” said Thomas.

Public health officials are already calling for urgent federal intervention to ensure equitable access. Some have suggested expanding the Ryan White HIV/AIDS Program or creating a national HIV prevention fund — similar to the federal government’s vaccine rollout program during COVID-19.

A Global Lifeline

Outside the U.S., Yeztugo could prove lifesaving. In sub-Saharan Africa, where women — particularly adolescent girls — face disproportionate HIV risk, the ease of twice-yearly injections could revolutionize prevention.

“Daily pills aren’t realistic for many of the people who need protection the most,” said Dr. Noma Mkwanazi, a clinician in Johannesburg. “This is the first HIV prevention method that truly meets them where they are.”

International organizations, including UNAIDS and WHO, have already begun negotiating access deals with Gilead to bring Yeztugo to the global South. But similar efforts in the past were slow and limited by U.S. patent protections.

The Road Ahead

The approval of Yeztugo marks a critical turning point — one that could finally bring the HIV pandemic under control. But the drug’s success hinges not only on science, but also on politics, equity, and public will.

“This is our polio vaccine moment,” said Dr. Brooks. “Let’s not waste it.”

Whether Yeztugo becomes a universal tool for prevention — or yet another miracle medicine reserved for the privileged few — will be determined in the months ahead. The cure may not be here yet, but for the first time in decades, the future looks like it might belong to prevention.